CAJ | 학술논문

目的:评价肾炎康复片联合厄贝沙坦治疗慢性肾脏疾病的有效性.方法:将80例 CKD 患者随机分为两组,肾炎康复片联合厄贝沙坦组(治疗组)40例,厄贝沙坦组(对照组)40例,疗程为12周,两组均观察治疗前后24h 尿蛋白定量,肾功(血肌酐、血尿素氮、血尿酸及 eGFR),血浆白蛋白,C 反应蛋白及中医症候积分.结果:两组治疗后24h 尿蛋白定量、肾功、ALB、中医症候积分(面色无华、少气乏力、腰痛及浮肿)均较治疗前明显改善,差异有统计学意义(P<0.05);治疗组与对照组相比,治疗后24h 尿蛋白定量、UA、ALB、CRP 及面色无华、少气乏力、手足心热、口干咽燥等中医症候积分改善均优于对照组,差异有统计学意义(P<0.05).结论:肾炎康复片联合双倍剂量厄贝沙坦能有效延缓 CKD 进展,改善机体微炎症状态,并有效缓解患者主观症状,提高生存质量.
목적:평개신염강복편연합액패사탄치료만성신장질병적유효성.방법:장80례 CKD 환자수궤분위량조,신염강복편연합액패사탄조(치료조)40례,액패사탄조(대조조)40례,료정위12주,량조균관찰치료전후24h 뇨단백정량,신공(혈기항、혈뇨소담、혈뇨산급 eGFR),혈장백단백,C 반응단백급중의증후적분.결과:량조치료후24h 뇨단백정량、신공、ALB、중의증후적분(면색무화、소기핍력、요통급부종)균교치료전명현개선,차이유통계학의의(P<0.05);치료조여대조조상비,치료후24h 뇨단백정량、UA、ALB、CRP 급면색무화、소기핍력、수족심열、구간인조등중의증후적분개선균우우대조조,차이유통계학의의(P<0.05).결론:신염강복편연합쌍배제량액패사탄능유효연완 CKD 진전,개선궤체미염증상태,병유효완해환자주관증상,제고생존질량.
Objective: To investigate the therapeutic effects of Shenyan Kangfu Tablet (SYKFT) and double-dose irbesartan on chronic kidney disease(CKD). Methods: 80 CKD patients were randomly divided into two groups, 40 patients in each group. The treatment group was given SYKFT and double-dose irbesartan treatment, while the control group was only given double-dose irbesartan. Both groups were treated for 12 weeks. The urine protein content, kidney function parameters, plasma-albumin content, C reactive protein content and accumulated points of TCM syndromes of both groups 24 hours before and after treatment were observed. Results: The urine protein content, kidney function parameters, ALB and accumulated points of TCM syndromes of both groups 24 hours after treatment significantly improved compared with pretreatment, with significant differences (P<0.05). The urine protein content, UA, ALB, CRP and accumulated points of TCM syndromes in the treated group 24 hours after treatment were significantly better than those in the control group (P<0.05). Conclusion: SYKFT and double-dose irbesartan can delay the progression of CKD, improve the inflammational state and enhance the prognosis.